Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Catherine M. Lockhart"'
Autor:
Aaron B. Mendelsohn, Young Hee Nam, James Marshall, Cara L. McDermott, Bharati Kochar, Michael D. Kappelman, Jeffrey S. Brown, Catherine M. Lockhart
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 1, Pp n/a-n/a (2021)
Abstract We report utilization patterns and characteristics of patients treated with biologic anti‐inflammatory agents in a large commercially insured patient population in the United States. We identified adult (age ≥18 years) patients receiving
Externí odkaz:
https://doaj.org/article/1cf89d930c90443cb5ca9898ef8be72c
Publikováno v:
Journal of Virus Eradication, Vol 4, Iss 2, Pp 118-122 (2018)
Objective:We conducted a meta-analysis of randomised studies that assessed the effectiveness of directly observed hepatitis C medication therapy delivered in outpatient clinics compared to treatment as usual.Methods:We completed a systematic literatu
Externí odkaz:
https://doaj.org/article/25841da870ef472eb7cc3884016e4cd5
Autor:
Catherine M. Lockhart, Cara L. McDermott, Aaron B. Mendelsohn, James Marshall, Ali McBride, Gary Yee, Minghui Sam Li, Aziza Jamal-Allial, Djeneba Audrey Djibo, Gabriela Vazquez Benitez, Terese A. DeFor, Pamala A. Pawloski
Publikováno v:
Journal of Medical Economics. 26:403-410
Autor:
Jeffrey S Brown, Aaron B Mendelsohn, Young Hee Nam, Judith C Maro, Noelle M Cocoros, Carla Rodriguez-Watson, Catherine M Lockhart, Richard Platt, Robert Ball, Gerald J Dal Pan, Sengwee Toh
Publikováno v:
J Am Med Inform Assoc
The US Food and Drug Administration (FDA) created the Sentinel System in response to a requirement in the FDA Amendments Act of 2007 that the agency establish a system for monitoring risks associated with drug and biologic products using data from di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2378074056dcd6608f99d0c90e14ad8
https://europepmc.org/articles/PMC9667154/
https://europepmc.org/articles/PMC9667154/
Autor:
Pamala A. Pawloski, Cara L. McDermott, Gabriela Vazquez Benitez, Terese A. DeFor, Aaron B. Mendelsohn, James Marshall, Erick Moyneur, Catherine M. Lockhart
Publikováno v:
Blood. 140:13254-13255
Autor:
Jeffrey S. Brown, Aaron B. Mendelsohn, Catherine M Lockhart, James Marshall, Cara L. McDermott, Pamala A. Pawloski
Publikováno v:
Drugs-Real World Outcomes
Background Data on short-acting recombinant granulocyte colony-stimulating factor (G-CSF) biosimilar utilization from claims data in the USA are limited. Objective To evaluate patient baseline characteristics and utilization patterns for short-acting
Autor:
James Marshall, Charles E. Barr, Jie Zhang, Jeffrey S. Brown, Cynthia Holmes, Bernadette Eichelberger, Jeffrey R. Curtis, Neil A. Accortt, Kevin Haynes, Cheryl N. McMahill-Walraven, Gayathri Sridhar, Jerry Clewell, Catherine M Lockhart
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 26:417-490
There is a need for postmarketing evidence generation for novel biologics and biosimilars.To assess the feasibility, strengths, and limitations of the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) Distributed Research Network (
Autor:
Jeffrey S. Brown, Catherine M Lockhart, James Marshall, Pamala A. Pawloski, Aaron B. Mendelsohn, Cara L. McDermott
Publikováno v:
Journal of the National Comprehensive Cancer Network. 18:HSR20-097
Autor:
James Marshall, Aaron B. Mendelsohn, Seoyoung C. Kim, Mengdong He, Charles E. Barr, Adrian J. Santiago Ortiz, Jeffrey R. Curtis, Catherine M Lockhart
Publikováno v:
Pharmacoepidemiology and Drug Safety. 29:770-777
Purpose The Centers for Medicare and Medicaid Services (CMS) mandated the transition from ICD-9 to ICD-10 codes on October 1, 2015. Postmarketing surveillance of newly marketed drugs, including novel biologics and biosimilars, requires a robust appro
Autor:
Huifeng Yun, Aaron B. Mendelsohn, Katelyn J. King, Cynthia Holmes, Annemarie Kline, Charles E. Barr, Jie Zhang, Jeffrey S. Brown, Catherine M Lockhart, James Marshall, Kai Yeung, James Kenney, Cara L. McDermott, Kevin Haynes, John Barron
Publikováno v:
Pharmacoepidemiology and Drug Safety. 29:778-785
Purpose To assess the capture of biologics (originator and biosimilar) in the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) Distributed Research Network (DRN), with a focus on medical claim National Drug Code (NDC), a new data